HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Jaffray, A. Articles by Rybicki, E. P. Search for Related Content PubMed PubMed Citation Articles by Jaffray, A. Articles by Rybicki, E. P. Agricola Articles by Jaffray, A. Articles by Rybicki, E. P.

Human immunodeficiency virus type 1 subtype C Gag virus-like particle boost substantially improves the immune response to a subtype C gag DNA vaccine in mice

¹ Department of Molecular and Cell Biology, Faculty of Science, University of Cape Town, Rondebosch 7701, South Africa
² MRC Liver Research Centre, Department of Medicine, University of Cape Town, Observatory 7925, South Africa
³ Division of Virology, University of Cape Town, Observatory 7925, South Africa
⁴ Institute of Infectious Diseases and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Observatory 7925, South Africa
⁵ National Health Laboratory Service, University of Cape Town, Observatory 7925, South Africa

Correspondence
Edward P. Rybicki
ed{at}science.uct.ac.za

Human immunodeficiency virus type 1 (HIV-1) subtype C is the predominant HIV in southern Africa, and is the target of a number of recent vaccine candidates. It has been proposed that a heterologous prime/boost vaccination strategy may result in stronger, broader and more prolonged immune responses. Since HIV-1 Gag Pr55 polyprotein can assemble into virus-like particles (VLPs) which have been shown to induce a strong cellular immune response in animals, we showed that a typical southern African subtype C Pr55 protein expressed in insect cells via recombinant baculovirus could form VLPs. We then used the baculovirus-produced VLPs as a boost to a subtype C HIV-1 gag DNA prime vaccination in mice. This study shows that a low dose of HIV-1 subtype C Gag VLPs can significantly boost the immune response to a single subtype C gag DNA inoculation in mice. These results suggest a possible vaccination regimen for humans.

This article has been cited by other articles:

				G. K. Chege, E. G. Shephard, A. Meyers, J. van Harmelen, C. Williamson, A. Lynch, C. M. Gray, E. P. Rybicki, and A.-L. Williamson HIV-1 subtype C Pr55gag virus-like particle vaccine efficiently boosts baboons primed with a matched DNA vaccine J. Gen. Virol., September 1, 2008; 89(9): 2214 - 2227. [Abstract] [Full Text] [PDF]

				V. Buffa, D. R. M. Negri, P. Leone, R. Bona, M. Borghi, I. Bacigalupo, D. Carlei, C. Sgadari, B. Ensoli, and A. Cara A single administration of lentiviral vectors expressing either full-length human immunodeficiency virus 1 (HIV-1)HXB2 Rev/Env or codon-optimized HIV-1JR-FL gp120 generates durable immune responses in mice J. Gen. Virol., June 1, 2006; 87(6): 1625 - 1634. [Abstract] [Full Text] [PDF]

				N. Larke, A. Murphy, C. Wirblich, D. Teoh, M. J. Estcourt, A. J. McMichael, P. Roy, and T. Hanke Induction of Human Immunodeficiency Virus Type 1-Specific T Cells by a Bluetongue Virus Tubule-Vectored Vaccine Prime-Recombinant Modified Virus Ankara Boost Regimen J. Virol., December 1, 2005; 79(23): 14822 - 14833. [Abstract] [Full Text] [PDF]